ArticleClinical pharmacology and therapeutics2026

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Thomas E Kraft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.